To assess safety and tolerability at increasing dose levels of IO-202 in successive cohorts of participants with relapsed or refractory monocytic AML and CMML in order to estimate the MTD or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D)
I/II - A combination of phases: (1) Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants; and (2) Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Pathology - SOM
University of Colorado Hospital
Protocol Number: 20-1388
More information available at ClinicalTrials.gov: NCT04372433
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers